PCV91 THE COST-EFFECTIVENESS OF ROSUVASTATIN VERSUS ATORVASTATIN FOR THE PREVENTION OF CARDIOVASCULAR MORBIDITY AND MORTALITY IN PATIENTS WITH HIGH BASELINE RISK-A SWEDISH ECONOMIC EVALUATION OF THE JUPITER TRIAL
Nov 1, 2010, 00:00 AM
10.1016/S1098-3015(11)72433-0
https://www.valueinhealthjournal.com/article/S1098-3015(11)72433-0/fulltext
Section Title :
RESEARCH POSTER ABSTRACTS
Section Order :
592
First Page :
A358
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(11)72433-0&doi=10.1016/S1098-3015(11)72433-0